

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Examiner: D.M. Sullivan
)	
Bush et al.)	Group Art Unit: 1636
)	
Serial No.: 10/574,167)	Docket No.: 8028-007-US
)	
Filed: March 29, 2006)	Submitted: December 20, 2007
)	
For: USE OF CELL LINES TO)	
PRODUCE ACTIVE THERAPEUTIC)	
PROTEINS)	

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
[submitted via EFS-Web]

Dear Sir:

This document is a Third Supplemental Information Disclosure Statement to the above-cited patent application.

Attached is at least one form PTO/SB/08A/B listing documents believed relevant to the subject application. The submission of the following information is not intended, nor should it be construed, to constitute an admission that any patent, article, or other information referred to herein is "prior art" unless specifically designated as such. In accordance with 37 C.F.R. § 1.97(b), the filing of this information shall not be construed to mean that a search has been made or that no other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is believed that this disclosure complies with the requirements of 37 C.F.R. § 1.96, § 1.97, and § 1.98 and the Manual of Patent Examining Procedures § 707.05(b). If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned at (858) 450-0099 x302 so that any deficiencies can be remedied.

This Third Supplemental Information Disclosure Statement is being submitted before the mailing date of an Office Action on the merits for the above-identified patent application. Accordingly, no fee is due for the filing of this Information Disclosure Statement under 37 C.F.R. § 1.97(b)(3).

A copy of each document is enclosed, except for issued United States patents and published United States patent applications pursuant to 37 C.F.R. § 1.98(a)(2)(ii). Some of the documents may have markings thereon. No significance is to be attached to the markings. These documents are not necessarily analogous art. Additionally, the order of the following documents is to be accorded no particular import, as the order thereof is completely fortuitous.

It is respectfully requested that these documents be: (1) fully considered by the Patent and Trademark Office during the prosecution of this application; and (2) represented on any patent which may issue on the application. Applicant respectfully requests that copies of the forms PTO/SB/08A/B, as considered and initialed by the Examiner, be returned with the next communication.

A publication, C.D. Woodworth & H.C. Isom, "Regulation of Albumin Gene Expression in a Series of Rat Hepatocyte Cell Lines Immortalized by Simian Virus 40 and Maintained in Chemically Defined Medium," Mol. Cell. Biol. 7: 3740-3748 (1987).

A publication, N. Martin-Vandelet et al., "Assembly and Secretion of Recombinant Chains of Human Inter- α -Trypsin Inhibitor in COS-7 Cells," Eur. J. Biochem. 259: 476-484 (1999).

A publication, S. Yang et al., "Administration of Human Inter- α -Inhibitors Maintains Hemodynamic Stability and Improves Survival During Sepsis," Crit. Care Med. 30: 617-622 (2002).

If any issues remain, the Examiner is respectfully requested to telephone the undersigned at (858) 200-0581.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Michael B. Farber", written over a horizontal line.

Michael B. Farber, Ph.D.
Reg. No.: 32,612

Date: December 20, 2007

CATALYST LAW GROUP, APC
9710 Scranton Road, Suite 170
San Diego, California 92121
(858) 450-0099
(858) 450-9834 (Fax)